News Sarepta Therapeutics, Inc.

Stocks

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 13/06/2026 am IST			5-day change	1st Jan Change
15.31 ^USD	+2.07%		-2.79%	-28.86%

08/06	Sarepta Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 10:40 AM
04/06	Sarepta Therapeutics, Inc. - Shareholder/Analyst Call

All News

Mentions Relevance

08/06	Sarepta Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 10:40 AM
04/06	Sarepta Therapeutics, Inc. - Shareholder/Analyst Call
04/06	Acting US FDA chief meets with rare disease groups to mend fences	RE
02/06	Sarepta Therapeutics to Participate in Upcoming Investor Conferences	BU
01/06	Edgewise to sell muscle dystrophy business to Servier for up to $2.65 billion	RE
14/05	Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference	BU
08/05	Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says	MT
07/05	Sarepta Therapeutics, Inc., Q1 2026 Earnings Call, May 06, 2026
07/05	Sarepta Therapeutics : 1Q 2026 Earnings Results Presentation	PU
07/05	Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Reports Q1 Revenue $730.8M	MT
07/05	Sarepta Therapeutics: Q1 Earnings Snapshot	AQ
07/05	Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Posts Q1 Adjusted EPS $3.16 per Share	MT
07/05	Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments	BU
07/05	Sarepta Therapeutics, Inc. Reiterates Revenue Guidance for the Year 2026	CI
07/05	Sarepta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
22/04	Sarepta Therapeutics to Announce First Quarter 2026 Financial Results	BU
17/04	Sarepta Therapeutics Seen Benefiting From New Elevidys Study, Better US Uptake in Second Half of 2026	MT
07/04	RBC Adjusts Price Target on Sarepta Therapeutics to $19 From $18, Maintains Sector Perform Rating	MT
01/04	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
26/03	Deutsche Bank Raises Price Target on Sarepta Therapeutics to $14 From $12, Keeps Sell Rating	MT
26/03	Wedbush Raises Price Target on Sarepta Therapeutics to $35 From $29, Keeps Outperform Rating	MT
25/03	Top Midday Gainers	MT
25/03	Sarepta Therapeutics, Inc. - Special Call
25/03	Sarepta Therapeutics : Preliminary Phase 1 2 Clinical Data Readout for DM1 and FSHD Programs	PU
25/03	Sarepta Therapeutics Announces First Clinical Data from Sirna Pipeline Targeting FSHD1 and DM1	CI